Pricing Log in Create free account
Saturday 17 October 2026 Export BDSX’s income statement to Excel — free account

Biodesix, Inc.

BDSX Healthcare Diagnostics & Research

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.66 1.05 −4.25%
Market cap
$260.7M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
−7.46
Beneish M
−3.13
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.12
Total sells 0.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — 2 — — — — — — 2 — —
Sell 5 — 5 10 — — — — — — — —
Insider Ownership 54.45%

Capital & Financial Ratios $m

Market Cap 260.72
Revenue 102.94
Net Income (27.76)
Free Cash Flow (20.40)
Net Debt 16.82
Current Ratio 2.85 (at or above 1.5: strong)
Debt/Equity 5.12 (above 2: weak)
P/E ratio 0.00
Fwd P/E (5.12) (negative: loss-making)
P/S ratio 2.37
P/B ratio 26.64 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 42.77% (at or above 15%: strong)
Next Y EPS Growth 37.57% (at or above 15%: strong)
Next Y revenue growth 26.56% (at or above 10%: strong)
Next 5Y EPS Growth 39.91% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.5×, against a ten-year median of 2.4×; over the ten years it ranged from 0.8× in 2022 to 7.5× in 2021.
P/S against its own 10 years 53.57%
10-year low 10-year high
P/B against its own 10 years 82.90%
10-year low 10-year high
EV/Sales against its own 10 years 58.71%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 26 26 19 30
Receivables 8 9 9 9
Inventory — — — —
Other 6 5 4 4
40 39 33 44
2023 2024 2025 Q'26
Payables 3 2 3 2
ST’ Debt 0 0 0 —
Other 22 1 1 1
33 14 17 15

Compound Annual Growth %

10y 5y 3y
Sales — 14.20% 32.31%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 26 27 — — —
’25 18 20 22 29 88
’24 15 18 18 20 71
’23 9 12 13 15 49
’22 7 11 11 10 38
’21 29 12 7 7 55
’20 5 4 9 27 46
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (10) (2) — — —
’25 (9) (7) (9) 1 (23)
’24 (15) (19) (11) (4) (49)
’23 (8) 1 (4) (12) (23)
’22 (13) (10) (10) (12) (45)
’21 (11) 1 (8) (10) (28)
’20 (5) (4) (4) (9) (21)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (10) (2) — — —
’25 (9) (7) (9) 1 (24)
’24 (16) (21) (11) (5) (52)
’23 (15) (6) (10) (15) (46)
’22 (13) (10) (11) (14) (49)
’21 (12) 1 (9) (11) (31)
’20 (5) (4) (5) (9) (24)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.81) (0.71) — — —
’25 (1.60) (1.60) (1.16) (0.49) (4.67)
’24 (2.80) (1.60) (1.40) (1.20) (6.60)
’23 (4.80) (3.40) (2.80) (2.00) (12.80)
’22 (10.00) (8.00) (6.80) (7.00) (31.00)
’21 (5.20) (8.20) (8.20) (9.80) (31.60)
’20 (743.68) (601.16) (638.60) (5.00) (129.60)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 217.00 80.40 19.10 20.60 22.20 3.44

Analyst estimates 2026–2028

Powerpack
High — — — — 420.30 639.80 119.94 50.60 44.20 31.00
People
People Employees — — — — 200 218 245 217 273 334
Revenue/emp, $m — — 0.00 0.00 0.23 0.25 0.16 0.23 0.26 0.26
Income, $m
Income, $m Revenue — — 20 25 46 55 38 49 71 88
Gross margin, % — — 78.44 75.26 51.71 44.01 62.96 73.50 78.17 81.11
EBT — — (26) (31) (31) (43) (65) (52) (43) (35)
EBT margin, % — — (128.06) (125.15) (68.81) (79.18) (171.27) (106.23) (60.19) (39.85)
Net income — 0 (26) (31) (31) (43) (65) (52) (43) (35)
Depreciation — — 2 3 9 6 11 11 8 7
Per share, $
Per share, $ Revenue — — 0.77 2,029.09 188.33 39.83 18.15 11.96 11.02 11.72
Earnings — — (0.99) (2,539.34) (129.60) (31.60) (31.00) (12.80) (6.60) (4.67)
Cash flow — — (0.67) (1,795.54) (88.33) (20.63) (21.36) (5.57) (7.52) (3.08)
Capex — — 0.00 (117.02) (9.00) (1.86) (1.68) (5.62) (0.53) (0.05)
Free cash flow — — (0.67) (1,912.56) (97.33) (22.49) (23.04) (11.19) (8.05) (3.14)
Book value — — (7.46) (18,606.53) 170.18 14.42 9.79 1.12 3.23 (0.33)
Shares, m — — 27 0 0 1 2 4 6 8
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 0.13 0.13 2.14 2.66 2.26 2.98 2.78 0.58
P/B — — 0.00 0.00 2.37 7.34 4.19 31.91 9.48 0.00
EV/Sales — — 1.92 1.92 1.39 2.24 1.79 3.16 2.92 0.90
EV/FCF — — (2.50) (2.50) (2.68) (3.97) (1.41) (3.38) (4.00) (3.37)
Cash, $m
Cash, $m Operating cash flow — — (18) (22) (21) (28) (45) (23) (49) (23)
Capex — — (1) (1) (2) (3) (4) (23) (3) 0
Free cash flow — — (18) (23) (24) (31) (49) (46) (52) (24)
Balance, $m
Balance, $m Working capital — — 5 (10) 54 15 30 6 25 15
Total debt — — 23 36 28 10 25 35 36 47
Net debt — — 17 31 (34) (23) (18) 9 10 28
Shareholders’ equity — — (198) (225) 41 20 21 5 21 (2)
Returns, %
Returns, % ROA — — (133.99) (73.08) (37.75) (43.78) (77.45) (54.32) (43.73) (38.18)
ROIC — — 0.00 0.00 (210.60) 0.00 (1,229.75) (190.38) (69.42) (67.00)
ROE — — 12.37 14.52 34.08 (141.75) (324.53) (414.09) (337.30) (383.09)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Biodesix, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%) Compare
FLGT Fulgent Genetics, Inc. $587.2M — (loss-making) — (loss-making) +4.38% (above 0%: growing) n/m +25.36% (above 0%: growing) 30.07% (42.25%) Compare
MYGN Myriad Genetics, Inc. $416.1M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
BDSX Biodesix, Inc. $260.7M — (loss-making) — (loss-making) +34.18% (above 0%: growing) n/m +72.75% (above 0%: growing) 82.06% (20.06%)
XGN Exagen Inc. $207.4M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
BNR Burning Rock Biotech Limited Sponsored ADR $137.1M — (loss-making) 11.1× −4.22% (below 0%: shrinking) n/m +46.01% (above 0%: growing) 72.58% (13.36%) Compare
MDXHF MedX Health Corp. $103.2M — (loss-making) — (loss-making) +33.59% (above 0%: growing) n/m +41.60% (above 0%: growing) 37.19% (1,027.95%) Compare
IMDX Insight Molecular Diagnostics Inc. $100.1M — (loss-making) — (loss-making) −53.86% (below 0%: shrinking) n/m −54.02% (below 0%: shrinking) 65.69% (4,770.71%) Compare
QUCY Quantum Cyber N.V $95.1M — (loss-making) — (loss-making) +11.12% (above 0%: growing) n/m +26.73% (above 0%: growing) 62.71% 0.00% Compare
Median of peers $172.2M — — +7.75% — +34.17% 64.20% (16.88%)

All 52 Diagnostics & Research stocks →

Biodesix, Inc. (BDSX) key facts

  • Strength: Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.
  • Biodesix, Inc. (BDSX) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BDSX traded at $23.66, a market capitalization of $260.7 million.
  • Return on equity was −383.1% and debt-to-equity 5.12.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −7.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Biodesix, Inc. (BDSX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BDSX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com